2023
Adjuvant immunotherapy in renal cell carcinoma: A living systematic review and network meta-analysis (NMA).
Sipra Q, Bin Riaz I, Naqvi S, He H, Siddiqi R, Islam M, Asghar N, Ikram W, Xu W, Singh P, Ho T, Bilen M, Zakharia Y, Bryce A. Adjuvant immunotherapy in renal cell carcinoma: A living systematic review and network meta-analysis (NMA). Journal Of Clinical Oncology 2023, 41: 694-694. DOI: 10.1200/jco.2023.41.6_suppl.694.Peer-Reviewed Original ResearchRenal cell carcinomaDisease-free survivalAdjuvant immunotherapyBaseline riskCell carcinomaTreatment optionsImproved disease-free survivalLocalized Renal Cell CarcinomaRisk categoriesAdjuvant treatment optionsAbsolute risk differenceUnique treatment optionRisk stratification systemMixed treatment comparisonSignificant differencesRelative effect estimatesEvidence synthesis frameworkAdjuvant pembrolizumabNivolumab-ipilimumabOverall survivalTreatment landscapeAbsolute benefitPreferred treatmentRecent trialsDisease progressionReal-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis.
Naqvi S, He H, Siddiqi R, Khan N, Khakwani K, Ayaz A, Singh P, Ho T, Bryce A, McGregor B, Xu W, Bin Riaz I. Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis. Journal Of Clinical Oncology 2023, 41: 695-695. DOI: 10.1200/jco.2023.41.6_suppl.695.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMixed treatment comparisonGraphical user interfaceTreatment comparisonsRule-based algorithmSystematic reviewUser interfaceSignificant PFS benefitAdditional survival benefitFirst-line treatmentCertainty of evidenceEfficacious treatment optionRenal cell carcinomaBayesian networkSignificant differencesQuality of lifeAutomated fashionRisk of toxicityEvidence synthesis frameworkImmunotherapy combinationsMRCC patientsOS benefitPFS benefitSynthesis frameworkTreatment toxicity
2022
Treatment of cancer associated thrombosis: A living interactive systematic review and bayesian network meta-analysis.
Sipra Q, Bin Riaz I, Naqvi S, He H, Liu H, Bryce A, Murad M, McBane R. Treatment of cancer associated thrombosis: A living interactive systematic review and bayesian network meta-analysis. Journal Of Clinical Oncology 2022, 40: e24070-e24070. DOI: 10.1200/jco.2022.40.16_suppl.e24070.Peer-Reviewed Original ResearchNet clinical benefitMixed treatment comparisonMajor bleedingClinical benefitSystematic reviewCANVAS trialOdds ratioGreater net clinical benefitRelevant non-major bleedingSignificant differencesTreatment comparisonsEffect estimatesEfficacy of DOACsNon-major bleedingVTE risk reductionVenous thromboembolism recurrenceCumulative ranking curvePatient-important outcomesConfidence intervalsMantel-Haenszel methodTreatment of catsFixed-effects modelThromboembolism recurrenceVTE recurrenceCause mortality